Buckhead Capital Management LLC held its stake in Medtronic plc. (NYSE:MDT) during the first quarter, according to its most recent disclosure with the SEC. The fund owned 3,870 shares of the medical technology company’s stock at the end of the first quarter. Buckhead Capital Management LLC’s holdings in Medtronic plc. were worth $312,000 as of its most recent filing with the SEC.
Other large investors have also recently bought and sold shares of the company. Sunbelt Securities Inc. purchased a new stake in Medtronic plc. during the fourth quarter worth $105,000. Norway Savings Bank bought a new position in shares of Medtronic plc. during the fourth quarter worth approximately $115,000. TLP Group LLC bought a new position in shares of Medtronic plc. during the third quarter worth approximately $124,000. Birch Hill Investment Advisors LLC acquired a new stake in Medtronic plc. during the third quarter worth about $128,000. Finally, Intellectus Partners LLC acquired a new stake in Medtronic plc. during the fourth quarter worth about $130,000. 82.71% of the stock is owned by institutional investors.
Medtronic plc. (NYSE:MDT) traded up 0.85% during trading on Friday, hitting $83.10. The stock had a trading volume of 1,839,368 shares. The firm has a 50 day moving average price of $81.93 and a 200-day moving average price of $78.41. The firm has a market capitalization of $113.75 billion, a PE ratio of 29.33 and a beta of 0.97. Medtronic plc. has a 1-year low of $69.35 and a 1-year high of $89.27.
Medtronic plc. (NYSE:MDT) last announced its earnings results on Tuesday, February 21st. The medical technology company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.11 by $0.01. Medtronic plc. had a net margin of 14.63% and a return on equity of 12.36%. The company had revenue of $7.28 billion during the quarter, compared to analyst estimates of $7.22 billion. During the same period in the previous year, the business earned $1.06 earnings per share. The firm’s quarterly revenue was up 5.0% compared to the same quarter last year. On average, equities research analysts expect that Medtronic plc. will post $4.58 EPS for the current year.
COPYRIGHT VIOLATION WARNING: “Medtronic plc. (MDT) Stake Maintained by Buckhead Capital Management LLC” was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/05/19/buckhead-capital-management-llc-has-312000-position-in-medtronic-plc-mdt-updated.html.
A number of analysts have issued reports on MDT shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $84.00 target price on shares of Medtronic plc. in a report on Monday, February 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $88.00 price objective on shares of Medtronic plc. in a research report on Friday, February 17th. Wedbush reiterated a “neutral” rating and issued a $85.00 price objective on shares of Medtronic plc. in a research report on Wednesday, February 22nd. Evercore ISI raised their target price on Medtronic plc. from $78.00 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, February 21st. Finally, Vetr downgraded Medtronic plc. from a “buy” rating to a “hold” rating and set a $80.67 target price for the company. in a research report on Thursday, February 16th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and fifteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $87.17.
In other Medtronic plc. news, EVP Hoedt Rob Ten sold 50,757 shares of the business’s stock in a transaction on Monday, March 20th. The shares were sold at an average price of $81.58, for a total value of $4,140,756.06. Following the completion of the sale, the executive vice president now directly owns 59,392 shares of the company’s stock, valued at $4,845,199.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Hooman Hakami sold 52,316 shares of the business’s stock in a transaction on Thursday, March 2nd. The stock was sold at an average price of $82.33, for a total transaction of $4,307,176.28. Following the completion of the sale, the executive vice president now directly owns 73,800 shares of the company’s stock, valued at $6,075,954. The disclosure for this sale can be found here. Insiders sold 198,073 shares of company stock valued at $16,315,832 over the last quarter. 0.25% of the stock is owned by company insiders.
About Medtronic plc.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic plc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic plc. and related companies with MarketBeat.com's FREE daily email newsletter.